{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:33:11Z","timestamp":1778679191933,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI17-00232"],"award-info":[{"award-number":["FIS PI17-00232"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11\/01076"],"award-info":[{"award-number":["PI11\/01076"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17-01362"],"award-info":[{"award-number":["PI17-01362"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00139"],"award-info":[{"award-number":["PI16\/00139"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013410","name":"Instituto Nacional de Ciberseguridad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["FI-DGR2014"],"award-info":[{"award-number":["FI-DGR2014"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["201602.30.31"],"award-info":[{"award-number":["201602.30.31"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","award":["CB07\/08\/0016"],"award-info":[{"award-number":["CB07\/08\/0016"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.arteri.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T08:08:59Z","timestamp":1557734939000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice"],"prefix":"10.1016","volume":"31","author":[{"given":"Karen Alejandra","family":"M\u00e9ndez-Lara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina Nicoleta","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Pallar\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Carles","family":"Escol\u00e0-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Julve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2019.04.001_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2019.04.001_bib0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1194\/jlr.R039297","article-title":"Cardioprotective functions of HDLs","volume":"55","author":"Rye","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2019.04.001_bib0215","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/ATVBAHA.111.227181","article-title":"Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia","volume":"31","author":"Bellanger","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.arteri.2019.04.001_bib0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4137\/CMC.S5970","article-title":"Niacin or ezetimibe for patients with, or at risk of coronary heart disease","volume":"4","author":"Guthrie","year":"2010","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2013.06.006","article-title":"HPS2-THRIVE results: bad for niacin\/laropiprant, good for ezetimibe?","volume":"229","author":"Masana","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2019.04.001_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.numecd.2014.09.003","article-title":"Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials","volume":"25","author":"Verdoia","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2019.04.001_bib0240","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/eht064","article-title":"The difficult search for a \u2018partner\u2019 of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin","volume":"34","author":"Landmesser","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.04.001_bib0245","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.04.001_bib0250","article-title":"Niacin for primary and secondary prevention of cardiovascular events","volume":"6","author":"Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arteri.2019.04.001_bib0255","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","article-title":"HDL and cardiovascular disease","volume":"384","author":"Rader","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.04.001_bib0260","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.04.001_bib0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbalip.2016.03.004","article-title":"HDL functionality in reverse cholesterol transport \u2013 challenges in translating data emerging from mouse models to human disease","volume":"1861","author":"Lee-Rueckert","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.arteri.2019.04.001_bib0270","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/14656566.2012.690395","article-title":"Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety","volume":"13","author":"Yadav","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.arteri.2019.04.001_bib0275","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2019.04.001_bib0280","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacl.2013.06.007","article-title":"Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients","volume":"7","author":"Franceschini","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0285","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jacc.2013.07.025","article-title":"The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality","volume":"62","author":"Khera","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0290","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1161\/ATVBAHA.115.306268","article-title":"Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects","volume":"36","author":"Ronsein","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0295","doi-asserted-by":"crossref","first-page":"e0136934","DOI":"10.1371\/journal.pone.0136934","article-title":"Cholesteryl ester turnover in obese insulin-resistant dogs","volume":"10","author":"Le Bloc\u2019h","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.arteri.2019.04.001_bib0300","first-page":"A439","article-title":"Niacin does not accelerate reverse cholesterol transport in man","volume":"33","author":"Dunbar","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0305","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/ATVBAHA.109.198226","article-title":"Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome","volume":"30","author":"Julve","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0310","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-2929-0_15","article-title":"Quantification of in vitro macrophage cholesterol efflux and in vivo macrophage-specific reverse cholesterol transport","volume":"1339","author":"Escola-Gil","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0315","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1194\/jlr.M200081-JLR200","article-title":"Mechanisms of HDL deficiency in mice overexpressing human apoA-II","volume":"43","author":"Julve","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2019.04.001_bib0320","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","article-title":"NAD(+) intermediates: the biology and therapeutic potential of NMN and NR","volume":"27","author":"Yoshino","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.arteri.2019.04.001_bib0325","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Canto","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.arteri.2019.04.001_bib0330","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","article-title":"Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice","volume":"14","author":"Yoshino","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.arteri.2019.04.001_bib0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.02.001","article-title":"Nicotinamide improves aspects of healthspan, but not lifespan, in mice","volume":"27","author":"Mitchell","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.arteri.2019.04.001_bib0340","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1161\/atvb.25.9.1896","article-title":"Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo","volume":"25","author":"Rotllan","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2019.04.001_bib0345","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.arteri.2019.04.001_bib0350","first-page":"8","article-title":"Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity","volume":"224","author":"Ness","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.arteri.2019.04.001_bib0355","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.nutr.28.061807.155443","article-title":"Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition","volume":"28","author":"Bogan","year":"2008","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.arteri.2019.04.001_bib0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0021-9258(19)45675-5","article-title":"The management of nicotinamide and nicotinic acid in the mouse","volume":"247","author":"Collins","year":"1972","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arteri.2019.04.001_bib0365","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0021-9258(18)96630-5","article-title":"On the relative efficacy of nicotinamide and nicotinic acid as precursors of nicotinamide adenine dinucleotide","volume":"241","author":"Petrack","year":"1966","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arteri.2019.04.001_bib0370","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/emmm.201403943","article-title":"Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3","volume":"6","author":"Khan","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.arteri.2019.04.001_bib0375","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12017-009-8058-1","article-title":"Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons","volume":"11","author":"Liu","year":"2009","journal-title":"Neuromol Med"},{"key":"10.1016\/j.arteri.2019.04.001_bib0380","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s00018-017-2527-8","article-title":"Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells","volume":"74","author":"Hwang","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.arteri.2019.04.001_bib0385","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nutres.2017.03.005","article-title":"Nicotinamide protects hepatocytes against palmitate-induced lipotoxicity via SIRT1-dependent autophagy induction","volume":"40","author":"Shen","year":"2017","journal-title":"Nutr Res"},{"key":"10.1016\/j.arteri.2019.04.001_bib0390","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/pr.110.003905","article-title":"Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?","volume":"64","author":"Canto","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.arteri.2019.04.001_bib0395","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2011.10.007","article-title":"Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation","volume":"14","author":"Qiang","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.arteri.2019.04.001_bib0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.07.032","article-title":"SIRT1 deacetylates and positively regulates the nuclear receptor LXR","volume":"28","author":"Li","year":"2007","journal-title":"Mol Cell"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:51:00Z","timestamp":1778676660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916819300476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0214916819300476"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2019.04.001","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}